1. Home
  2. PESI vs SABS Comparison

PESI vs SABS Comparison

Compare PESI & SABS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Perma-Fix Environmental Services Inc.

PESI

Perma-Fix Environmental Services Inc.

HOLD

Current Price

$17.46

Market Cap

370.3M

Sector

Industrials

ML Signal

HOLD

Logo SAB Biotherapeutics Inc.

SABS

SAB Biotherapeutics Inc.

HOLD

Current Price

$3.52

Market Cap

344.8M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
PESI
SABS
Founded
1990
2014
Country
United States
United States
Employees
307
N/A
Industry
Environmental Services
Biotechnology: Pharmaceutical Preparations
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
370.3M
344.8M
IPO Year
1996
2020

Fundamental Metrics

Financial Performance
Metric
PESI
SABS
Price
$17.46
$3.52
Analyst Decision
Strong Buy
Analyst Count
0
4
Target Price
N/A
$10.75
AVG Volume (30 Days)
267.6K
260.5K
Earning Date
05-08-2026
05-12-2026
Dividend Yield
N/A
N/A
EPS Growth
43.61
78.53
EPS
N/A
N/A
Revenue
$642,000.00
N/A
Revenue This Year
$34.62
N/A
Revenue Next Year
$77.02
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$8.58
$1.85
52 Week High
$21.32
$5.15

Technical Indicators

Market Signals
Indicator
PESI
SABS
Relative Strength Index (RSI) 46.61 45.42
Support Level $14.18 $3.39
Resistance Level $19.02 $4.02
Average True Range (ATR) 0.76 0.12
MACD -0.17 -0.02
Stochastic Oscillator 5.18 44.79

Price Performance

Historical Comparison
PESI
SABS

About PESI Perma-Fix Environmental Services Inc.

Perma-Fix Environmental Services Inc is a nuclear services company and provider of nuclear and mixed waste management services. The company's nuclear waste services include treatment and management of radioactive and mixed waste (waste containing both hazardous and low-level radioactive waste). The company operates through two segments: i) The treatment segment: It offers nuclear, low-level radioactive, Mixed, hazardous and non-hazardous waste treatment, processing and disposal services, and ii) the Services segment which generates the majority of the revenue, provides on-site waste management services to commercial and government customers, technology-based services, construction, logistics, and transportation services among others.

About SABS SAB Biotherapeutics Inc.

SAB Biotherapeutics Inc is a clinical-stage biopharmaceutical company focused on developing multi-specific, high-potency, human immunoglobulin G (hIgG) to treat and prevent immune and autoimmune disorders. The company's lead product candidate, SAB-142, targets autoimmune Type 1 Diabetes (T1D) with a disease-modifying therapeutic approach that aims to change the T1D treatment paradigm by delaying onset and potentially preventing disease progression of Stage 3 T1D patients. It is focused on developing product candidates for disease targets where a differentiated approach has the greatest potential to be either first-in-class against novel targets against complex targets to treat diseases, including type 1 diabetes (T1D) and other autoimmune disorders.

Share on Social Networks: